Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08XFA
|
|||
| Former ID |
DIB011538
|
|||
| Drug Name |
IL-2 XL
|
|||
| Synonyms |
IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel
Click to Show/Hide
|
|||
| Indication | Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64] | Phase 1/2 | [1] | |
| Company |
Flamel Technologies SA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020218) | |||
| REF 2 | Pharmacokinetics (PK) and immunologic responses in a phase I/II study of a sustained release formulation of IL-2 in renal cell carcinoma (RCC) patients. J Clin Oncol (Meeting Abstracts) June 2006 vol. 24 no. 18_suppl 2558. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.